36 year old man presenting with pancreatitis and a history of recent commencement of orlistat case report

Napier, Sarah; Thomas, M.

doi:10.1186/1475-2891-5-19

Cited by 28 publications

(18 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, orlistat is the only FDA (Food and Drug Administration) approved drug for long term management of obesity [14] . It has been reported that there has been an association between the use of orlistat and development of pancreatitis in some cases clinically with no evidence of biliary disease or alcohol consumption [15] . This study is concerned with the description of structural changes in rat pancreas following orlistat administration and whether these effects are dose dependent or not.…”

Section: Discussionmentioning

confidence: 99%

Effect of Orlistat on the pancreas of the female albino rat: Histological and Histochemical study

Abdelwahab

Ali

Mahmoud

2017

Journal of Medical Histology

View full text Add to dashboard Cite

Introduction: Orlistat is the only FDA approved drug for long term management of obesity. It reduces the absorption of dietary fat by inhibiting lipase enzyme. Many cases of pancreatitis were clinically reported in people who used orlistat. Aim of The work:The aim of the present study is to shed a light on the possible deleterious effect of orlistat on the normal pancreatic tissue, and the molecular mechanisms beyond these changes. Materials & Methods: Thirty six female albino rats were divided into 4 groups: Control Group I (a) without treatment &I (b) received only1 ml fish oil. Group II received 30 mg/kg/day of orlistat dissolved in 1ml of fish oil orally for 8 weeks. Group III, received 40 mg/kg/day of orlistat .Group IV (a) & (b) withdrawal groups. Pancreas was dissected out and processed for histological and immunohistochemical study for CASPASE, TNF, INOS and INSULIN. Results: Orlistat caused variable degrees of pancreatic tissue degeneration, dilatation of pancreatic ducts with retained secretion, fatty degeneration and congestion. Inflammatory cells infiltration observed in both pancreatic acini and islets of Langerhan,s only with high dose (40mg/kg). Positive immunoreactivity for activated caspase 3 and iNOS being more evident in high dose and decrease in immunoreactivity for anti-insulin antibody. immunoreactivity for TNF-α had been shown in high dose. These effects disappear after low dose withdrawal only. Conclusion: Orlistat may induce inflammation, fatty degeneration and impaired insulin production in the pancreas. These effects are dose dependent, and it should be taken in consideration while prescribing orlistat as a treatment for obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Orlistat on the pancreas of the female albino rat: Histological and Histochemical study

Abdelwahab

Ali

Mahmoud

2017

Journal of Medical Histology

View full text Add to dashboard Cite

show abstract

“…Acute renal failure with oxalate crystal deposition [158,159] Gastro-esophageal reflux disease [160] Additive adverse GI events with olestra-containing foods [161] Increased INR after the addition of orlistat [104] Two women with bulimia nervosa used orlistat to purge following binge [162] Acute kidney injury secondary to acute oxalate nephropathy [163] Myopathy after 27 months of orlistat [164] Acute pancreatitis [165] Jaundice and acute cholestatic hepatitis [166] Hepatocellular necrosis [167] Cutaneous leukocytoclastic vasculitis [168] Diabetic ketoacidosis [169] GI: Gastrointestinal; INR: International normalized ratio. where the lack of effect on sustained linear growth and lack of potential for development of dependency assume even greater importance.…”

Section: Expert Opinionmentioning

confidence: 99%

Orlistat: current status in clinical therapeutics

McClendon

Riche

Uwaifo

2009

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…The published version will differ from this one as a result of linguistic and technical corrections and layout editing. 8 …”

Section: Wwwftbcomhrmentioning

confidence: 99%

“…Although orlistat has displayed very promising results for obesity treatment, unfortunately it is associated with a number of unpleasant gastrointestinal side effects (8). Natural products provide an ample scope for the discovery of pancreatic lipase inhibitors that can perhaps be developed into anti-obesity drugs (9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

Proteinaceous Pancreatic Lipase Inhibitor from the Seed of Litchi chinensis

Mhatre¹,

Bhagit²,

Yadav³

2018

Food Technol. Biotechnol.

View full text Add to dashboard Cite

SummaryA study on the pancreatic lipase inhibitory activity of protein from the seed of Litchi chinensis was carried out. Protein was isolated by 70 % ammonium sulphate precipitation followed by dialysis. Lipase inhibitory activity of the protein was evaluated using both synthetic (pnitrophenyl palmitate) and natural (olive oil) substrate. Protein at the final concentration of 100 µg/mL was able to inhibit pancreatic lipase with 68.15 % inhibition on synthetic substrate and 60 % inhibition on natural substrate.Proteinaceous nature of the inhibitor was determined using trypsinization assay. Pancreatic lipase inhibitory protein was sensitive to 0.05 % trypsin treatment with loss of 61.9 % activity. IC50 of this proteinaceous pancreatic lipase inhibitor was 73.099 µg/mL using synthetic substrate. This inhibitory protein was sensitive to pH with highest inhibitory activity at pH = 8.0 and lowest at pH = 3.0. Protein was further analyzed on 10 % non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and interestingly it showed the presence of a single band of (61 ± 2) kDa stained by Commassie  Corresponding author: Phone: +9102227432890, 02227437693; Fax: 02227431094; E-mail: raman.yadav@mgmmumbai.ac.in ORCID IDs: 0000-0001-5593-7018 (Mhatre), 0000-0003-2623-1811 (Bhagit), Food Technology and Biotechnology 56 (2) 2018 www. ftb.com.hr Please note that this is an unedited version of the manuscript that has been accepted for publication. This version will undergo copyediting and typesetting before its final form for publication. We are providing this version as a service to our readers. The published version will differ from this one as a result of linguistic and technical corrections and layout editing.2 brilliant blue. Protein band was further isolated from gel which showed 98.29 % purity on highperformance liquid chromatography. Isolated protein was finally crystallized to see the homogeneity of protein by batch crystallization method. Crystals were well formed with distinct edges. Isolated protein showed good pancreatic lipase inhibitory activity.

show abstract

36 year old man presenting with pancreatitis and a history of recent commencement of orlistat case report

Abstract: Background: Orlistat is an anti-obesity drug licensed in the United Kingdom for 7 years. We present a case of a patient who developed pancreatitis four days after commencing orlistat.

Cited by 28 publications

References 3 publications

Effect of Orlistat on the pancreas of the female albino rat: Histological and Histochemical study

Effect of Orlistat on the pancreas of the female albino rat: Histological and Histochemical study

Orlistat: current status in clinical therapeutics

Proteinaceous Pancreatic Lipase Inhibitor from the Seed of Litchi chinensis

Contact Info

Product

Resources

About